Perceptive Advisors LLC Purchases 69,735 Shares of Abivax SA Sponsored ADR $ABVX

Perceptive Advisors LLC increased its position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 17.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 458,343 shares of the company’s stock after acquiring an additional 69,735 shares during the quarter. Abivax comprises 1.1% of Perceptive Advisors LLC’s holdings, making the stock its 29th biggest position. Perceptive Advisors LLC’s holdings in Abivax were worth $61,810,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Jefferies Financial Group Inc. bought a new position in shares of Abivax during the 3rd quarter worth approximately $38,827,000. Persistent Asset Partners Ltd bought a new position in shares of Abivax during the 3rd quarter worth approximately $815,000. Nan Fung Trinity HK Ltd. raised its stake in shares of Abivax by 11.8% during the 4th quarter. Nan Fung Trinity HK Ltd. now owns 113,365 shares of the company’s stock worth $15,288,000 after acquiring an additional 12,000 shares in the last quarter. Atika Capital Management LLC bought a new position in shares of Abivax during the 3rd quarter worth approximately $5,858,000. Finally, Total Clarity Wealth Management Inc. bought a new position in shares of Abivax during the 4th quarter worth approximately $1,247,000. Institutional investors own 47.91% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on ABVX. Citizens Jmp boosted their price objective on shares of Abivax from $131.00 to $187.00 and gave the stock a “market outperform” rating in a research note on Tuesday, June 2nd. Wolfe Research set a $136.00 price target on shares of Abivax in a research note on Wednesday, June 3rd. Citigroup restated an “outperform” rating on shares of Abivax in a research note on Tuesday, June 2nd. Wall Street Zen upgraded shares of Abivax from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Finally, Truist Financial cut their price target on shares of Abivax from $140.00 to $135.00 and set a “buy” rating on the stock in a research note on Tuesday, June 2nd. Twelve research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $130.08.

Abivax Trading Up 2.7%

Shares of Abivax stock opened at $100.15 on Thursday. Abivax SA Sponsored ADR has a 12-month low of $5.69 and a 12-month high of $148.83. The firm has a market capitalization of $7.99 billion, a price-to-earnings ratio of -19.22 and a beta of 0.69. The firm’s 50 day simple moving average is $114.81 and its two-hundred day simple moving average is $118.49.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings results on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The company had revenue of $1.56 million for the quarter, compared to analyst estimates of $0.40 million. On average, sell-side analysts predict that Abivax SA Sponsored ADR will post -3.4 EPS for the current fiscal year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.